Sign in

    Timothy Chiang

    Senior Research Analyst at Capital One

    Timothy Chiang is a Senior Research Analyst at Capital One, specializing in financial analysis and investment strategy within the banking and financial services sector. Leveraging his expertise, he provides key insights for Capital One’s investment decisions, although specific company coverage details and quantitative performance metrics such as success rates or rankings are not publicly available. His career at Capital One is marked by a focus on rigorous research and financial modeling, but publicly available records do not indicate prior firms or a detailed timeline of his professional experience. While his credentials and securities licenses are not explicitly listed in current sources, his senior analyst role suggests a strong background in financial services and industry-standard qualifications.

    Timothy Chiang's questions to Outlook Therapeutics (OTLK) leadership

    Timothy Chiang's questions to Outlook Therapeutics (OTLK) leadership • Q3 2024

    Question

    Timothy Chiang asked about the outcomes of the recent Type C and Type D meetings with the FDA and whether there was a correlation between these discussions and the BLA resubmission timeline being moved to Q1 2025.

    Answer

    Executive C. Trenary clarified that there is no correlation between the FDA meetings and the filing timeline; the delay is solely related to the projected completion of trial enrollment. He characterized the FDA discussions as very positive, confirming they have reviewed every CMC question from the CRL with the agency and are satisfied with the outcomes.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to Outlook Therapeutics (OTLK) leadership • Q2 2024

    Question

    Timothy Chiang asked about the preparations being made by contract manufacturers and packaging partners for the upcoming European and U.S. launches, and whether any further remediation was needed ahead of FDA meetings.

    Answer

    Executive C. Trenary confirmed that inventory is already on hand from manufacturing partners Fujifilm, Ajinomoto, and PCI, awaiting final labeling post-approval. He clarified that no more Type A meetings are planned, but ongoing Type C and D meetings are being held at the FDA's suggestion. This proactive engagement is intended to resolve all CMC questions from the CRL and streamline the BLA resubmission and review process.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to IRONWOOD PHARMACEUTICALS (IRWD) leadership

    Timothy Chiang's questions to IRONWOOD PHARMACEUTICALS (IRWD) leadership • Q2 2024

    Question

    Timothy Chiang asked about Ironwood's interactions with patient advocacy groups for apraglutide, whether payer discussions have begun, and followed up on LINZESS JV commercial margins and the Q2 gross-to-net adjustment.

    Answer

    Chief Medical Officer Michael Shetzline confirmed strong links and enthusiastic feedback from patient advocacy groups, who appreciate the once-weekly dosing. COO & CFO Sravan Emany addressed the financial questions, stating the company remains focused on maximizing LINZESS brand profit and that the revised guidance fully accounts for the increased Medicaid utilization expected for the remainder of the year.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to IRONWOOD PHARMACEUTICALS (IRWD) leadership • Q1 2024

    Question

    Timothy Chiang asked if earlier-week data from the STARS study for the CIC patient population would be presented at DDW, particularly for secondary endpoints. He also inquired about the high placebo effect seen in the study and whether certain secondary endpoint data could be included on the drug's label.

    Answer

    CMO Michael Shetzline confirmed that earlier-week data for CIC patients, including 24-week data, will be presented at DDW and will support the drug's efficacy. He clarified that the placebo rate on the primary endpoint was low (12.5%), and the higher rate on a 48-week secondary endpoint could be due to the novel endpoint and the study's weaning algorithm. While acknowledging the challenge, he stated they will work to get as much supportive data as possible into the final label.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to AKYA leadership

    Timothy Chiang's questions to AKYA leadership • Q2 2024

    Question

    Inquired about the scale of the July restructuring compared to January's and its potential impact on revenue. Also asked for the key drivers to improve gross margin to the low-60% range by year-end.

    Answer

    The July restructuring was similar in scale to the one in January and is not expected to impact revenue. Gross margin expansion will be driven by revenue mix, higher volume to absorb fixed costs, and significantly improved inventory management due to the new in-house manufacturing capabilities.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to AKYA leadership • Q1 2024

    Question

    Sought clarification on the expected growth trajectory through 2024, the speed of recovery for reagent revenue growth, and the achievability of 60% gross margins in the second half of the year.

    Answer

    The company expects a sequential improvement in growth throughout the year, rather than a sudden jump in Q2, to reach historical growth rates by Q4. Reagent revenue growth is expected to recover relatively quickly now that manufacturing is fully operational. Management affirmed that 60% gross margins are achievable in the back half of the year, supported by strong product margins and increasing revenue to cover fixed costs.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to ISR leadership

    Timothy Chiang's questions to ISR leadership • Q3 2022

    Question

    Timothy Chiang of Northland Capital Markets asked if hospital staffing shortages were still a headwind for procedure volumes. He also questioned if the current R&D expense was a good run rate, inquired about the balance between virtual and in-person physician training, and asked about business development plans given the company's cash position.

    Answer

    Executive Lori Holmes-Woods confirmed that employment pressures, particularly in hospitals, continue to be a factor affecting patient volumes. She stated that IsoRay will offer both virtual and in-person training to accommodate physician preferences and that the company is actively pursuing business development opportunities, supported by increased market research spending. Chief Financial Officer Jonathan Hunt added that the current R&D expense level is a reasonable run rate for the near future.

    Ask Fintool Equity Research AI

    Timothy Chiang's questions to ISR leadership • Q2 2022

    Question

    Timothy Chiang of Northland Capital Markets questioned the timeline for full enrollment of the Cesium-131 KEYTRUDA combination study, sought confirmation on the plan to hire three more sales reps and their potential revenue impact, and asked about any plans to invest in training programs at U.S. medical schools to increase resident education on brachytherapy.

    Answer

    CEO Lori Holmes-Woods explained that COVID-19 has made predicting the KEYTRUDA study's enrollment timeline difficult, but they are working to accelerate it by making it a multicenter study. She confirmed the plan to add three sales territories over the next 12 months, stating that while it's hard to quantify the revenue impact, more 'feet on the ground' will help accelerate adoption. Regarding medical school training, she acknowledged its importance and said that while they are not currently involved with a specific institution, they engage with residents through societies like the American Brachytherapy Society (ABS) and conferences like IPCU to provide training on Cesium-131.

    Ask Fintool Equity Research AI